Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05894876 · ClinicalTrials.gov registry record
A Study of the Genetic Basis of Response to Growth Hormone Treatment in Children With Idiopathic Short Stature
A clinical trial, sponsored by Novo Nordisk A/S.
- Terminated
- Registry status
- 43
- Enrollment target
NCT05894876 is a clinical trial that was terminated before completion, run by Novo Nordisk A/S. The registered enrollment target is 43 participants.
The verdict
NCT05894876 was terminated before completion, sponsored by Novo Nordisk A/S.
- TERMINATED
- Registry status
- 43 participants
- Enrollment target
Study Summary
The study doctor will collect information from participants with Idiopathic Short Stature, who were treated with growth hormone for at least a year when they were children, before they reached puberty. The word "Idiopathic" refers to "unknown cause", and as such the study participants have/had short stature with no identifiable medical cause. The purpose of the study is to identify differences in the genetic characteristics of participants who responded well or poorly to growth hormone therapy. No medications or other treatments are provided to the participants by Novo Nordisk as part of this study. The study will last for up to 1 year. The participants will attend their usual doctor's appointments. If the participants are not usually visiting the clinic, they will need to do it only once as part of this study. If the participant agrees to take part in the study, they will be asked to read and sign the 'Agreement to take part form'.
Interventions
- OTHER No treatment is given
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2024-04-29 |
| Est. Completion | 2025-03-21 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05894876
The ClinicalTrials.gov registry entry for NCT05894876 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which No treatment is given is the first listed.
NCT05894876 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05894876 about?
NCT05894876 is a clinical study titled "A Study of the Genetic Basis of Response to Growth Hormone Treatment in Children With Idiopathic Short Stature". The study doctor will collect information from participants with Idiopathic Short Stature, who were treated with growth hormone for at least a year when they were children, before they reached puberty. The word "Idiopathic" refers to "unknown cause", and as such the study participants have/had short...
What is the current status of trial NCT05894876?
This trial is currently terminated. The enrollment target is 43 participants. The study started on 2024-04-29. Estimated completion is 2025-03-21.
What interventions are being tested in trial NCT05894876?
The interventions under investigation include: No treatment is given (OTHER).
Who is sponsoring clinical trial NCT05894876?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.